Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01833 PA GOODDOCTOR
RTNominal down97.550 -2.350 (-2.352%)
Research Report

05/02/2021 11:16

{I-bank focus}Goldman cuts PA Good Doctor to HK$120.37

[ET Net News Agency, 5 February 2021] Goldman Sachs cut its target price for Ping An
Good Doctor (PAGD) (01833) to HK$120.37 from HK$130 and maintained its "buy" rating.
The research house said PAGD reported better-than-estimated revenue with in-line gross
profit for 2020. Online medical services remain the key driver with strong growth in
average daily consultations.
The company initiated three strategic upgrades in mid-2020. Goldman expects these will
lead to a higher SG&A expense in the following two years (2021-22). Hence, it postponed
the break-even time to 2025.
Goldman revised its earnings estimates in 2021/22 to Rmb-1.2bn/Rmb-809mn to factor in
strategic investment and potential foreign exchange loss. (KL)

Remark: Real time quote last updated: 12/04/2021 13:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.